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Many public health responses and modeled scenarios for COVID-19 outbreaks caused by
SARS-CoV-2 assume that infection results in an immune response that protects individuals
from future infections or illness for some amount of time. The presence or absence of
protective immunity due to infection or vaccination (when available) will affect future
transmission and illness severity. Here, we review the scientific literature on antibody
immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV, MERS-
CoV and endemic human coronaviruses (HCoVs). We reviewed 2,452 abstracts and iden-
tified 491 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of
protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5)
population seroprevalence. While further studies of SARS-CoV-2 are necessary to determine
immune responses, evidence from other coronaviruses can provide clues and guide future
research.
https://doi.org/10.1038/s41467-020-18450-4 OPEN
1 Department of Biology, University of Florida, Gainesville, FL, USA. 2 Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA. 3 Department of
Virology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. 4 National Human Genome Research Institute, National Institutes of
Health, Bethesda, MD, USA. 5Department of Comparative, Diagnostic & Population Medicine, University of Florida, Gainesville, FL, USA. 6 Division of HIV,
ID, and Global Medicine, University of California, San Francisco, CA, USA. 7Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,
Baltimore, MD, USA. 8Department of Genetics, University of Cambridge, Cambridge, UK. 9Mathematical Modelling of Infectious Diseases Unit, Institut
Pasteur, Paris, France. 10 Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA. 11These authors contributed equally: Angkana T. Huang,
Bernardo Garcia-Carreras, Matt D. T. Hitchings, Bingyi Yang, Leah C. Katzelnick. ✉email: datc@ufl.edu
NATURE COMMUNICATIONS |         (2020) 11:4704 | https://doi.org/10.1038/s41467-020-18450-4 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
A pandemic of severe acute respiratory syndrome cor-onavirus 2 (SARS-CoV-21–3) is currently underway, andis resulting in severe morbidity and mortality worldwide.
Limited pre-existing immunity to this virus is thought to be
responsible for the explosive increase in cases. Nearly all trans-
mission models of SARS-CoV-2 assume that infection produces
immunity to reinfection for durations of at least 1 year1–3. This
assumption is relevant to public health officials implementing and
managing various nonpharmaceutical interventions, the utility of
sera from infected individuals as a therapeutic4, and the ability for
serological tests to identify those who are immune5. The
dynamics of immunity will also affect the performance of ser-
ological testing to quantify the extent of infection in populations.
However, knowledge of the dynamics and nature of immune
response to SARS-CoV-2 infection is limited, and the scientific
basis for durable immunity, upon which these key public health
and clinical strategies are dependent, is not well developed.
In the context of our current limited understanding of SARS-
CoV-2 immunity, this review looks for insights from studies of
the broader coronavirus family. Several authors have noted
human experimental infection studies (called human challenge
studies), suggesting that protection after coronavirus infections
may last for only 1 or 2 years6–9. Human coronaviruses (HCoVs)
have been used in human challenge experiments since shortly
after their discovery in 196510,11. These experiments, where
individuals were intentionally infected with HCoV, provide some
of the clearest characterization of human responses to cor-
onaviruses and the potential for immune responses to limit
infection and disease. Multiple human challenge studies mea-
sured antibody immunity before a coronavirus challenge and
identified antibody responses that were associated with protection
from infection, serological response, or symptoms12. The low
severity of HCoV allowed for safe use of these viruses6–9 as
human challenge. The greater likelihood of severe illness in
SARS-CoV-2 limits the applicability of such experiments,
although some have argued for their use in subsets of the
population13.
The duration of immunity to SARS-CoV-2 will dictate the
overall course of the pandemic and post-pandemic dynamics7,
and so an understanding of the temporal dynamics of protective
immunity is critical. As with other introductions of novel
pathogens14, explosive outbreaks of SARS-CoV-2 across the globe
may threaten its persistence by reducing the number of available
hosts susceptible to infection. Immune interactions with endemic
coronaviruses could theoretically affect the short- and long-term
dynamics of SARS-CoV-2, and vice versa15,16 through cross-
protection or antibody-dependent enhancement17, but these
interactions and effects are not yet understood. If SARS-CoV-2
does become endemic, age-stratified seroprevalence studies of
endemic coronaviruses may provide insight into incidence rates
in the presence of higher levels of population immunity.
Here, we describe the results of a systematic review of literature
on antibody measures of immunity to coronaviruses, including
endemic HCoV (principally HCoV-229E, HCoV-HKU1, HCoV-
OC43, and HCoV-NL63), SARS-CoV (severe acute respiratory
syndrome coronavirus that emerged in 2002), MERS-CoV
(Middle East respiratory syndrome coronavirus), and early
work on SARS-CoV-2. We conceptualize the stages of exposure
and infection at which immunity may play a role in the dynamics
of SARS-CoV-2, and how literature describing work on this and
other coronaviruses can provide insights into these stages, as
follows (see Fig. 1, a visual abstract of our review). First, an
exposure to a pathogen generates an antibody response that
changes over time and between individuals (antibody kinetics).
Upon exposure, infection history might play a role in providing
protection against new infection, and the literature can provide
evidence for such correlates of protection through challenge
studies and longitudinal cohort studies. Upon infection, an
individual’s immune state, possibly impacted by pre-existing
antibodies to other coronaviruses (among other mechanisms),
may cause harm through immunopathogenesis, and the literature
on this topic primarily consists of in vitro experiments. Correlates
of immunity (or risk through immunopathogenesis) are com-
plicated by the existence of multiple genera of coronaviruses that
are antigenically diverse and may provide cross-protection, and
which may also cause false-positive assay results due to cross-
reactivity. Finally, the preceding phenomena at the individual
level interact to determine population seroprevalence. Studies that
measure these quantities across different age groups can provide
evidence, albeit ecological evidence, for or against the proposed
mechanisms of immunity at the individual level.
Results
Paper identification. Our searches identified 2452 abstracts of
potential relevance (Supplementary Fig. 1). Two reviewers read
each abstract and identified 491 papers for full review. Papers
were classified into our areas of focus. Below, we present the
findings of our review for each area of focus.
General background: serological assays. Multiple serological
assays have been used to characterize antibody responses to
coronaviruses. Assays we encountered in our review fell into two
major categories (Supplementary Table 1). The most commonly
used assays were binding assays, including enzyme-linked
immunosorbent assays (ELISA), immunofluorescence assays
(IFA), western blots, and complement fixation (CF). Hemagglu-
tination inhibition assays (HAI), which measure the ability of
antibodies in sera to prevent binding of virus to red blood cells,
have previously been used for coronaviruses, but are no longer
common. The final category of assays was neutralization assays.
Neutralization assays are typically considered the gold standard
for measuring functional antibody responses as they measure
biological activity throughout the viral replication process.
Researchers have used assays of both types to characterize anti-
body activity by antibody class (i.e., IgG, IgM, and IgA). As these
antibodies are known to have different temporal dynamics, we
reported when specific classes of antibodies were characterized in
the figures. If no characterization was specified, we reported the
measures of antibody aggregated across all classes. The source of
samples in the reviewed studies was almost exclusively serum
samples. However, mucosal samples collected by swab or nasal
washings were also reported.
Antibody responses: kinetics and clinical severity. Initially,
164 studies were classified as relevant to antibody kinetics and to
the association of antibody responses with clinical severity. Of
these, 58 were selected after further review. Supplementary
Table 2 provides summaries for some of these studies. We digi-
tized data from a subset of 51 studies that included sufficient
detail on longitudinal antibody measurements (Supplementary
Data 1; 5 on endemic HCoVs, 11 on MERS-CoV, 34 on SARS-
CoV, and 2 on SARS-CoV-2 (one of which is non-peer-reviewed
preprint)). In all, 8% of studies reported cumulative seroconver-
sion only. In total, 60% of the digitized studies provided estimates
during the first week after the onset of symptoms, while 75% had
measurements at least 1 month after the onset of symptoms18.
In the studies we shortlisted, antibody responses to infecting
coronaviruses were rarely reported during the acute phase of
illness (1–7 days)19–26. Corman et al.26 detected antibodies in
both ELISA and neutralization tests in 24 of 27 MERS-CoV
patients within the first week. Many studies describe an immune
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response, characterized by a robust increment of antibody titers
for HCoV-229E, MERS-CoV, SARS-CoV, and SARS-CoV-2 after
the second or third week following the onset of illness8,20,23,26–37.
Callow et al.8 found similar dynamics in IgA and IgG across
ten individuals experimentally infected with HCoV-229E: anti-
body levels increased after 8 days and peaked around 14 days,
although significant variation between patients was reported.
Yang et al.21, analyzing the data across 67 patients, found higher
positive rates of IgM against SARS-CoV than IgG during the first
month. The proportion of patients who seroconverted for IgM
peaked 30 days after onset, followed by a gradual decrease of IgM
levels, while IgG levels peaked by week 2521. Using sera from 18
SARS-CoV patients, Mo et al.23 noted that IgM, IgG, and
neutralizing antibodies increased after day 15, and while IgM and
neutralizing antibodies peaked on day 30, IgG peaked on day 60.
Another study on 30 SARS-CoV-infected patients20 detected
seroconversion of IgM, IgG, and IgA at similar times, indicating
that the earliest they reached a peak was on average 15 days38.
While it is currently too early to characterize how anti-SARS-
CoV-2 antibodies will change over prolonged periods of time,
preliminary studies have analyzed antibody changes in recent
infections. Tan et al.39 found that IgM was detected on day 7 and
peaked on day 28 (across 28 patients), and IgG appeared by day
10 and peaked on day 49 (45 patients), while Zhao et al.40
determined that seroconversion among 173 patients took place at
median times of 12 (IgM), 14 (IgG), and 11 (neutralizing
antibodies) days.
Multiple studies reported that while IgM and IgG titers
increased during the first week following symptom onset, IgM
levels gradually waned (while remaining detectable) for SARS-
CoV and MERS-CoV in comparison to IgG levels about a month
post follow-up20,23,27. Most studies that examined antibody
kinetics over extended periods of time focused on IgG20,23,41–48.
Callow et al.8 found among experimental infections with
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Fig. 1 Aspects of antibody response included in this review. This figure shows the areas of focus of our review within our conceptualization of the stages
of exposure and infection at which we believe that antibody-mediated immunity may play a role in the dynamics of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). At the individual level (a), antibody response following the first infection/exposure increases and then declines (antibody
kinetics). Sometime later, individuals may be exposed to SARS-CoV-2 again. They may be protected from infection by their acquired immunity (correlates
of protection). Their acquired immunity may also moderate the severity of infection with some possibility that pre-existing immunity may lead to
immunopathogenesis (relevant to both first and second exposure). These individual-level dynamics aggregate to form the population-level seroprevalence.
b Measures of seroprevalence may imperfectly measure past exposure to infection due to antigenic diversity of future SARS-CoV-2 viruses and cross-
reactivity of endemic human coronaviruses (HCoVs) with SARS-CoV-2. c Measures of seroprevalence may also be inconsistent across times, as antibody
levels within individuals wane.
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HCoV-229E that after peaks in IgG and IgA, antibody levels
waned, and between 11 weeks and 1 year post inoculation, were at
similar levels to those found in inoculated but uninfected patients.
Other studies41,46 reported detectable IgG levels in recovered
MERS-CoV patients, respectively, at 5 months and 1 year after
illness onset, while another21 detected IgG antibodies across 67
SARS-CoV patients after 82 weeks, the endpoint of the study. We
found few studies that analyzed changes in antibody kinetics over
the course of many years after illness onset42,43. The 18 SARS-
CoV patients in Mo et al.23 were followed for 2 years; in that
study, after peaking, IgM levels were undetectable by day 180. On
the other hand, levels of IgG were still high on day 180 and
gradually declined to still detectable levels by day 720, while
neutralizing antibodies were detectable in 17 of 18 patients at day
720, but at low titers23. Cao et al.43 described similar long-term
dynamics for IgG and neutralizing antibodies over the course of a
3-year study on SARS-CoV: titers for both peaked at month 4,
and while they waned thereafter, 74.2% and 83.9% of patients had
detectable levels of IgG and neutralizing antibodies, respectively,
at month 36. Liu et al.47 found that a high proportion of 19
recovered SARS-CoV patients were positive up to 2 years post
infection, with the percentage declining in the third year, a
pattern similar to that found by Wu et al.49 in 18 patients50.
Some studies have explored a potential link between case
severity and antibody response; however, the available informa-
tion analyzing the nature of this relationship is uneven across
viruses. Several studies on MERS-CoV as well as the first
preliminary analyses on SARS-CoV-2 explicitly explore this
connection, while fewer studies on endemic HCoVs and SARS-
CoV do so. Several studies found that cases of varying severity
(e.g., asymptomatic, mild, and severe) developed detectable
antibodies against HCoV-229E, SARS-CoV, SARS-CoV-2, and
MERS-CoV28,30,39,43,46. One study51 found that the rise in
antibodies between acute and convalescent sera correlated
positively with symptoms and clinical score in 15 patients
experimentally infected with HCoV-229E (Table 1). However,
most studies of SARS-CoV did not report symptom severity, and
evidence of differences in antibody responses among cases
experiencing symptoms of different severity is inconclusive.
SARS-CoV survivors with sequelae were found to have lower
neutralizing antibodies than patients without sequelae43, although
the same study otherwise found no significant differences in
kinetics according to disease severity. Chan et al.45 found no
evidence of difference in antibody responses between patients
who survived or died52,53. In MERS-CoV, on the other hand, Ko
et al.28 found that both seroconversion rate and peak antibody
levels increased with disease severity, while Okba et al.54 reported
a robust response to severe infections as opposed to low or no
seroconversion in asymptomatic and mild cases. Milder infec-
tions also appeared to be less likely to elicit serologic
responses46,54, although Okba et al.54 suggest that seroconversion
detection may depend on the antibodies being specifically
assayed. More severe cases were also found to have slower
responses28,30; 75% of patients who died had not seroconverted
by week 328. Some authors have hypothesized54,55 that serocon-
version rates in severe cases may be associated with prolonged
viral shedding, and that low antibody responses in mild cases may
be due to short-lived infections. Another study46 suggested that
weaker antibody responses to endemic HCoVs (specifically
HCoV-229E) might be because these mainly infect the upper
respiratory tract. Preliminary studies on SARS-CoV-2 point to a
possibly contrasting pattern to MERS-CoV: while IgM antibodies
appear at the same time in severe and nonsevere cases, IgG
appears sooner in severe cases39. On the other hand, neutralizing
antibody titers were higher in severe cases40.
The distributions of time points at which antibodies were
detected (see “Methods”) in the digitized data are shown in Fig. 2.
The median time to detection across different antibodies was the
shortest for SARS-CoV-2 (11.0 days; interquartile range (IQR)
7.0–14.0 days), followed by SARS-CoV (14.0 days; IQR
10.0–18.0 days) and MERS-CoV (15.0 days; IQR 12.0–18.0 days).
Severity appears to be associated with time to detection of IgM in
MERS-CoV cases only (2 days longer), and IgG in both MERS-
CoV and SARS-CoV-2 (2–3 days longer for more severe cases).
All data on time to seroconversion were based on symptomatic
patients. No data were available for asymptomatic individuals.
Figure 3 provides a broad sense for trajectories of antibodies
(also see Supplementary Figs. 3 and 4). Most longer-term studies
(>10 weeks) were for MERS-CoV and reported IgG and
neutralizing antibodies; these showed the presence of IgG and
neutralizing antibodies up to 60 weeks after symptom onset
(Fig. 3). The studies reporting symptom severity with longer-term
data focused on MERS-CoV. Not all of these studies reported a
cutoff for the assay used; in those that did, two-thirds of
patients with mild symptoms had detectable or positive IgG
antibodies at 6 months and 1 year, while all patients with severe
symptoms had detectable IgG antibodies at the same points in
time (Table 2).
Correlates of protection. Identification of a correlate of protec-
tion requires characterization of immune responses prior to a
known exposure or period of risk in which infection or illness
outcomes are characterized. In our review, we found that this
level of detail was only present in human challenge experiments
with HCoVs. We identified 18 studies in which volunteers were
exposed to experimental infections with HCoV. Of these, six
associated pre-infection antibody measurements with virologic,
serologic, or illness outcomes upon experimental infection
(Supplementary Table 4).
The earliest identified experimental infection study of corona-
viruses found that seven of eight subjects with neutralizing titer
<5 excreted virus after experimental exposure compared to only
one of four subjects with pre-exposure titer of 40 or greater10.
Table 1 Key questions for SARS-CoV-2.
Key questions for SARS-CoV-2
• What are the kinetics of antibody-mediated immune responses to infection?
• Do people who have more severe disease mount stronger antibody responses after infection?
• How do antibody responses vary between different types of antibodies or as measured by different assays?
• How does the presence of antibodies impact the clinical course and severity of the disease?
• Is there cross-reactivity with different coronaviruses?
• Does cross-reactivity lead to cross-protection?
• Will infection protect you from future infection?
• How long will antibody-mediated immunity last?
• What are the antibody-based correlates of protection?
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Interestingly, this study is one of the few to report illness as a
function of dose of viral inoculum given in the challenge
experiment, and suggests that those given higher doses (>101.2
TCD50) were more likely to experience cold (10/15) than those
exposed to lower doses (<100.7 TCD50) (3/11).
Barrow et al.56 found that lower proportions of individuals
with high neutralizing titer experienced significant cold upon
viral challenge than individuals with low titer.
Callow12 characterized IgA, IgG, and neutralizing antibodies in
sera and nasal washings from 33 volunteers before they were
experimentally exposed to 229E HCoV. She found that multiple
antibody responses were associated with reduced risk of infection,
seroconversion, and symptomatic illness upon challenge. Indivi-
duals who seroconverted to the experimental viral exposure
(defined as a rise in ELISA IgG serum antibodies) had
significantly higher serum IgG, neutralizing antibodies, and nasal
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Fig. 3 MERS-CoV antibody kinetics. The top row shows the data for studies reporting IgG concentration in units of optical density, while the bottom row
shows the data for studies reporting neutralizing antibodies in units of titers. The columns correspond to different severity categories. Each line
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studies within each panel, as each lab may have different assay conditions resulting in different scales. See Supplementary Figs. 3 and 4 for (more limited)
the data on SARS-CoV and IgA. Colors reflect the severity categories: not reported (gray), mild (blue), and severe (red).
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IgA. Serum and mucosal IgA were associated with the duration of
viral shedding post experimental infection, with those shedding
for 5 days or more having statistically significantly less mucosal
IgA than those shedding less than 5 days (0.6 ng/ml vs. 4.7 ng/ml,
P < 0.01). Serum-neutralizing antibody was not found to be
significantly associated with viral shedding duration. This study
also showed protective associations of pre-infection serum-
neutralizing antibody, serum IgG, and nasal IgA with clinical
severity scores and nasal secretion weights (a measure of the
severity of rhinorrhea symptoms).
Another prospective study57 reported detection of pre-existing
neutralizing antibodies among medical students who had virus
isolation (67%, n= 8/12) or seroconversion to HCoV-229E (25%,
n= 3/12). Pre-existing neutralizing antibodies were inversely
associated with increases in neutralizing antibodies after reinfec-
tion, but were not associated with reinfection events that were
determined by CF seroconversion.
Several studies exposed volunteers to two viral challenges, some
months apart. Reed 9 rechallenged six volunteers who had been
experimentally infected with HCoV-229E 8–12 months pre-
viously9. On the first challenge, all six developed symptoms and
detectable viruses, and five of six experienced a significant rise in
titer. In the second, zero of six experienced illness, detectable
virus or significant rise in titer. Callow et al.8 rechallenged
volunteers with the same dose of HCoV-229E, 1 year apart. Of
nine volunteers who were infected in the first exposure, 6 (67%)
were infected in the second exposure. However, none of these
individuals developed respiratory illness symptoms and they
experienced a mean duration of detectable virus of 2 days
compared to a mean of 5.6 in the initial challenge. Of note, these
experimental doses may differ from the amounts of virus that
people are exposed to in natural infections.
Cross-reactivity and antigenic diversity. We identified 82 papers
as related to cross-reactivity and/or antigenic diversity (Supple-
mentary Table 5). Of these studies, 59 were identified as highly
important and were described in the text or tables, and data were
digitized from 7 studies (Supplementary Data 2 and Supple-
mentary Fig. 5). Figure 4 visually summarizes studies in this
section.
Within the Coronaviridae family, the Coronavirinae subfamily
includes four distinct genera. The Alphacoronaviruses include
two major human coronaviruses, HCoV-229E and HCoV-NL63.
Multiple HCoV-229E-like strains have also been characterized.
The Betacoronaviruses are categorized into four lineages. Lineage
A includes HCoV-OC43 and HCoV-HKU1, Lineage B includes
SARS-CoV and SARS-CoV-2, Lineage C includes MERS-CoV
and multiple bat coronaviruses, and Lineage D contains
coronaviruses thus far only identified in bats. HCoV-OC43 and
HCoV-229E are documented to cause common cold, while the
more recent strains (HCoV-HKU1 and HCoV-NL63) infect both
the upper and lower respiratory tract, resulting in more severe but
rarely fatal disease58. Other CoVs have been associated with
human disease, including enteric disease in infants and zoonotic
infections from livestock, but seem rare and are not described
here9,59–64.
Coronaviruses have four structural proteins: the spike protein
(S), the nucleocapsid (N), the envelope protein (E), and the
membrane protein (M)65,66. The S protein, which protrudes from
the virus envelope, is immunodominant50,67 and consists of two
subunits: the S1 protein, which contains the receptor-binding
domain (RBD) and the S2 protein, which mediates cell membrane
fusion68,69. The nucleocapsid protein, which is also immuno-
genic, is smaller than S, lacks a glycosylation site, and induces
antibodies sooner than to S during infection, making it an
attractive protein for diagnostic assay design70. Sequence
homology for the N and S of SARS-CoV to other Betacorona-
viruses is 33–47 and 29%, respectively, while homology to
Alphacoronaviruses is lower (25–29% homology to N and
23–25% for S)70. SARS-CoV-2 is most similar to SARS-CoV,
harboring sequence homology of 90% in N and 76% in S followed
by MERS-CoV (48% and 35%, respectively)71. Immunogenicity of
other proteins were less studied. Studies in HCoV-229E72 and
SARS-CoV73 suggest that M does have immunogenic epitopes,
despite its relatively small size but with titers rising at times later
than 21 days post infection, while responses to the E protein were
rarely detected. In contrast, another study detected anti-M
antibodies in over 80% of the individuals (n= 58) at 10 days
post onset, while detection of anti-N and anti-S increased later74.
The authors speculated these late detections as effects of their
antigen-purification procedures where the N protein may not be
able to exhibit its natural conformation as fragments of N were
able to be detected earlier.
Natural and experimental infection studies in humans point to
cross-reactivity within but minimal reactivity between endemic
human Alpha- and Betacoronaviruses. Individuals experimentally
inoculated with HCoV-229E and HCoV-229E-like strain LP
experienced a >4-fold rise in neutralizing antibodies to both
HCoV-229E and LP, while individuals inoculated with HCoV-
OC43 did not75. While volunteers experimentally inoculated with
HCoV-229E-like strains were protected against challenge with the
homologous strain at 1 year (n= 6/6; none shed virus, showed
symptoms, or had a rise in antibodies), volunteers experienced
only partial protection against heterologous HCoV-229E-like
strains (n= 5/12 protected). Increasing population immunity to
HCoV-229E in the population was associated with less clinical
disease upon challenge with HCoV-229E-like strains9. Studies of
serological responses to HCoV N proteins point to cross-
reactivity within Alpha-HCoVs (229E and NL63) and Beta-
HCoVs (OC43 and HKU1), but not between Alpha- and Beta-
HCoVs76–79. Consistent with observations in human challenge
studies, children experiencing natural HCoV infections experi-
ence fourfold seroconversions to either HCoV-OC43 or HCoV-
229E, but not both simultaneously80. However, a longitudinal
study in newborns found that children seroconverted to either
HCoV-NL63 or HCoV-229E but not both, although both viruses
Table 2 Proportion of patients that had detectable antibodies, at different time points.
Strain Weeks since symptom onset/infection Asymptomatic Mild symptoms Severe symptoms
HCov-229E 3 weeks 20% (1 of 5) 100% (10 of 10)
MERS-CoV 13 weeks 67% (10 of 15) 95% (18 of 19)
26 weeks 67% (8 of 12) 100% (10 of 10)
52 weeks 67% (8 of 12) 100% (8 of 8)
The time points were post symptom onset or infection, for HCoV-229E and MERS-CoV. The results for HCoV-229E are from Kraaijeveld et al.51, and report the number of individuals experiencing
symptoms of a given severity that had significant antibody rises post infection. The results for MERS-CoV are taken across studies in which a cutoff for the assay being used was provided, and gives the
number of patients for which IgG levels were above the respective cutoffs, at different time points (also see Fig. 3). For example, at week 26, there were 12 patients with mild symptoms from studies that
reported a cutoff, and 8 of those patients had IgG levels above that cutoff. MERS-CoV data were digitized from six studies28,33,41,46,54,152.
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are Alpha-HCoVs81. A later study in newborns followed from age
0 to 20 months82 showed asymmetric interactions within Alpha-
HCoVs and Beta-HCoVs: seroconversion to HCoV-NL63 was
observed after HCoV-229E, but no recent HCoV-229E serocon-
versions had a recent infection by HCoV-NL63, suggesting that
HCoV-NL63 provides at least short-term protective immunity
against HCoV-229E. Similarly, HCoV-HKU1 seroconversion
occurred prior to HCoV-OC43 but rarely after, suggesting that
HCoV-OC43 protected against HCoV-HKU1.
Infection with endemic HCoVs produces little cross-reactivity to
emerging CoVs SARS-CoV and MERS-CoV. Individuals experien-
cing natural infections with HCoV-OC43 or HCoV-229E did not
have detectable antibodies in acute or convalescent samples against
SARS-CoV (to N protein83 by IFA or neutralization45). Healthy
individuals with antibodies to HCoV-229E, HCoV-OC43, and
other endemic HCoVs rarely had detectable antibodies that bound
SARS-CoV-infected cells or SARS-CoV N protein78,84,85. HCoV-
OC43 N and SARS-CoV N proteins have a subset of sites with
shared homology, potentially explaining low-level false-positive
results for N-based assays86. Blood donors in Southern China (n=
152) and Saudi Arabia (n= 130) did not have detectable binding
(IFA) or neutralizing antibodies to either MERS-CoV or SARS-
CoV87,88. Because children experience less severe disease during
SARS-CoV infection than adults, it was hypothesized that child-
hood vaccination with non-CoVs provided cross-protection against
SARS-CoV. However, binding and neutralizing antibodies and T-
cell responses induced by routine childhood vaccinations (AMPV,
BCG, DPT, HBV, HIB, JEV, MMRV [MV and RV], OPV, PI, SV,
and VV (varicella vaccine)) did not cross-react with SARS-CoV in
experimentally inoculated mice89.
Emerging HCoVs can induce cross-reactive binding antibodies
toward endemic and other emerging HCoVs. SARS patients often
experience a > 4-fold rise in antibodies to HCoV-229E, HCoV-
NL63, and/or HCoV-OC43 in paired acute/convalescent samples
(n= 12/20)45. In one study, the number of SARS patients
who experienced a greater than fourfold rise in binding antibodies
was greater to HCoV-OC43 (n= 10/11) than HCoV-229E (n=
5/11)84. Some SARS patients also showed a rise in antibodies to
HCoV-229E and HCoV-OC43 N protein84 and HCoV-NL6376.
Among SARS-CoV patients (n= 28), 60% had detectable IFA
titers to MERS-CoV and 25% had anti-MERS-CoV- neutralizing
antibodies. A subset with available paired samples experienced
seroconversion to HCoV-OC43, but limited seroconversion to
Alpha-CoVs. In the same study, animal handlers at a wildlife
market in Guangzhou (n= 94) with low-level prevalence of
antibodies to SARS-CoV (13.8% by IFA measuring an antibody
bound to infected cells, 4.3% by NT) had detectable antibodies
toward MERS-CoV (2.2% by IFA)87. A follow-up study found
that the cross-reactivity between SARS-CoV and MERS-CoV was
unlikely to be due to similarity in the RBD, as monoclonal
antibodies (mAbs) raised to SARS-CoV RBD did not bind MERS-
CoV RBD or neutralize MERS-CoV even at high concentra-
tions90. MERS-CoV may produce less cross-reactivity against
SARS-CoV. A subset of slaughterhouse workers in Saudi Arabia
(a setting seen as potentially high risk for MERS-CoV exposure)
had antibodies to MERS-CoV by IFA as well as to endemic
HCoVs, but none had reactivity to SARS-CoV spike protein.
MERS-CoV patients were observed to have low-level cross-
reactivity to SARS-CoV88 and in one study HCoV-HKU1 N
protein76. Because of this cross-reactivity, researchers have
developed diagnostic assays with truncated SARS-CoV S, N,
and M proteins91–94. A study with longitudinal follow-up
suggests that the titers may indeed reflect stimulation of pre-
existing antibodies from past infections as avidity of IgG
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antibodies to HCoV-OC43 and/or HCoV-229E in two of their
SARS patients was high early on and remained high, while the
avidity against SARS-CoV was initially low24. See Fig. 4 for
associations between homologous and heterologous titers.
There is some evidence for antigenic evolution in the receptor-
binding domain of emerging CoVs. A study of SARS-CoV strains
from the zoonotic phase (palm civets and bats) to early and late in
the SARS epidemic revealed that some escaped neutralization by
mAbs targeting the spike RBD of SARS-CoV95–97. Sera from
BALB/c mice immunized with full-length S protein from civet
strains were ineffective against human SARS-CoV and vice
versa98. Despite significant cross-reactions between mAbs against
conformational epitopes of RBD with multiple mutational
differences, single mutations were shown to disrupt neutraliz-
ability99. In contrast, mAbs targeting regions critical for fusion
and entry on the S2 protein are immunogenic and can broadly
neutralize SARS-CoV strains65,100. A recent study showed
reduced binding of mAbs from SARS patients to the RBD of
SARS-CoV-2, especially those that blocked binding to the ACE2
receptor. The only mAb potently bound to SARS-CoV-2 RBD
protein did not compete with the RBD for binding to the ACE2
receptor, suggesting that it bound a different, conserved site on
the protein101. Similar studies were conducted to study changes in
MERS-CoV. Five recombinant RBD proteins were constructed
with mutations detected from MERS-CoV strains isolated in
humans (2012–2015) and camels102. These RBDs maintained
functionality and induced potent neutralizing antibodies. When
residues in their receptor-binding motifs were mutated to evade
neutralization, cross-reactivity persisted, but binding affinity to
DPP-4 (the main receptor for MERS-CoV) was lost, suggesting
limited antigenic escape for MERS-CoV. A study of MERS-CoV
isolates with distinct amino acid differences in the S and other
replication proteins found differences in replication kinetics, but
it is not clear that these were attributable to differences in S77.
Immunopathogenesis. In the initial review, 44 papers were
identified as related to immunopathogenesis. Of these, we found
26 sufficiently relevant to review in Supplementary Table 6, and
16 of those are detailed below and/or summarized in Fig. 5.
Antibody-dependent enhancement or other antibody-mediated
immunopathogenesis may be possible. Antibody-dependent
enhancement (ADE), where pre-existing antibodies increase
pathogenicity by facilitating viral entry into cells, a long
hypothesized explanation for severe dengue infections, has been
hypothesized to play a role in coronavirus pathogenesis
specifically in patients who seroconverted early in SARS-CoV
infection17,29,103. In support of a priming role from pre-existing
antibodies against endemic strains is the observation that older
patients infected with SARS-CoV appeared to mount an earlier
immune response with higher titers than younger patients103.
Authors from another study pointed toward enhancement from
antibodies within a single-infection episode17. Nasopharyngeal
viral load increased in the first week and declined thereafter, but
clinical worsening was seen in many of the patients at week 2,
with virus shedding in stool and urine observed toward the
end17,29. Many manifested with additional new lesions as original
lesions improved. The timing of the appearance of new lesions
correlated with IgG seroconversion and declined viral load,
suggesting that pathology post week 1 was driven by the immune
response rather than by uncontrolled viral replication. Others
have argued that ADE due to neutralizing antibodies is unlikely as
treatment of SARS-CoV with convalescent serum did not result in
adverse effects103.
Immunopathogenesis has been observed in a coronavirus of
cats, feline infectious peritonitis virus (FIPV). Kittens passively
immunized with serum-containing antibodies to FIPV developed
more rapid disease than controls not passively immunized104.
The authors noted similarity to dengue in humans where infants
with mid-levels of maternal antibody to dengue (compared to
high or low levels of maternal antibody) experience increased risk
of disease105. The one study that we found that addressed this
characterized endemic HCoV in infants106. They observed the
highest lower respiratory tract infection burden (7.8%) at
6–23 months of age (1.5% at <6 months, close to none at 2–5
years), while upper respiratory tract infection burden was close to
uniform106. The heightened disease burden after maternal
immunity waning to medium levels in the lower tract, and the
absence of such observation in the upper tract where antibodies
do not circulate, subtly supports the possibility of ADE in HCoVs.
Controlled in vitro experiments have explored the possible
enhancing action of antibodies for HCoV infections. A series of
studies by Yip et al. demonstrated that opsonization of anti-spike
antibodies allowed SARS-CoV to enter non-ACE2-expressing
immune cells that bear Fc-γ-RII (CD32)107,108. Though replica-
tion is observed after entry, the virus does neither exit nor alter
the expression of proinflammatory immune mediators (CCL2/
MCP-1, CCL3/MIP-1α, CXCL10/IP-10, and TNF-α) and
apoptosis-inducing ligands (FasL)109. This contrasts with the
effects in nonhuman primate studies where endocytosis into
macrophages stimulated inflammation, which in turn drives
severe lung injuries110. A study by another group in the human
promonocyte cell line (HL-CZ), which expresses both ACE2 and
Fc-γ-RII, demonstrated increased infectivity and virus-induced
apoptosis when anti-SARS-CoV sera from patients were added at
100- to 2000-fold dilutions, while at higher concentrations
neutralization occurred111. Upon infection, TNF-α, IL-4, and
IL-6 expressions heightened, while IL-3 and IL-1β only appeared
in trace amounts. The difference could have resulted from the cell
line differences or the set of mediators assessed109. Regarding
regions of the spike protein that may induce antibodies with
enhancement effects, both anti-S1a and anti-S1b mAbs showed
mild-to-moderate effects111. Only one particular anti-S1b clone
showed neutralization. No effect was seen for anti-N mAbs. There
is limited evidence that these mechanisms are causal to
inflammatory gene-expression differences among patients with
differing severities112.
While the link between antibody presence and enhanced
severity via infection of immune cells remains unclear, some have
suspected a role for autoreactive responses in increased severity of
illness. Prolonged tissue destruction can increase presentation of
host proteins to T- or B cells and result in an adaptive response
against self-, i.e., epitope spreading58. Increases in anticardiolipin
antibodies were reported in 33.9% of 62 post-SARS osteonecrosis
patients, but the lack of a comparison group of post-SARS
patients without osteonecrosis meant that the link was incon-
clusive113. Anti-S2 IgG antibodies targeting uninfected lung
epithelial cells (A549) were detected in SARS-CoV patients
20 days post symptom onset114, a reactivity not seen in serum
from healthy individuals and non-SARS-CoV pneumonia
patients. Complement inactivation only showed a cytotoxic effect
when IgG was present/unbounded. The presence of anti-S2
antibodies also increased the binding of immune cells (PBMCs)
to A549 cells treated with IFN-γ, replicating the conditions under
which a cytokine storm would be observed. A separate study
demonstrated colocalization of anti-S2 antibodies collected from
serum of SARS patients ≥50 days post fever onset with annexin
A2 and immunoprecipitated annexin A2 on A549 cell surfaces.
Elevated expression of annexin A2 on the surface can be
stimulated by IL-6 and IFN-γ, both cytokines induced by
SARS-CoV, which in turn increases binding of anti-S2 antibodies
to the cell. However, its pathogenic role was not explored115.
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Alternatively, similarity between viral and host epitopes (mole-
cular mimicry) can generate cross-reactive antibodies. In mice116
and humans117, there is evidence of anti-N antibodies that cross-
react with IL-11, an anti-inflammatory cytokine expressed in
many tissues, including the lung and bone marrow. The authors
suggest that high anti-N antibodies induced relatively early
during infection may be involved in the thrombocytopenia and
lymphopenia observed early in SARS-CoV infection116.
Population seroprevalence. From the paper review, 68 papers
were classified as having data on age and seroprevalence or ser-
oincidence, of which 20 studies were confirmed on further review,
and 14 had digitizable data. The age range across studies was 0 to
≥65, while the sample size of studies ranged from 69 to 19,974
(82–6400 for studies of endemic HCoVs). Supplementary Table 7
and Supplementary Data 3 contain details of the studies.
For endemic coronaviruses, seroprevalence rises sharply in
childhood, with little to no change in seroprevalence by age
among adults. While the exact dynamics from 6 months to 20
years vary between studies, the general trend remains consistent.
Figure 6 displays HCoV age-seroprevalence curves for six papers
with digitizable data on seroprevalence by age, with the panels
representing the four major endemic strains118–123. Trends from
papers not displayed in the figure are largely the same78,81,124,125.
Two studies show a marked decline in seroprevalence with age
above 4078,119.
The force of infection of endemic coronavirus strains is high,
and the age at first infection low, but variable across studies.
Simple catalytic models fit to the digitized data predict median
total force of infection across studies of 0.21 (95% CI 0.09, 0.40)
among immunologically naive individuals (see Fig. 6 for fitted
curves for each study and strain, and Supplementary Table 8 for
estimates by study and strain), corresponding to an average age at
first infection with any strain of 4.8 years (95% CI 2.5, 11.2). A
cohort of 25 infants followed from birth for an average of 2 years
experienced annual strain-specific incidence rates from 0.12 to
0.7081,82. Zhou et al.’s serosurvey measured IgG and IgM
separately, and showed very different patterns with age123. While
IgG seroprevalence rose to high levels by age 10 and remained
high into the adult population, IgM seroprevalence declined to
zero for all individuals aged 14 and older. The authors interpreted
this as evidence that first infections occurred before the age of 14
for all strains.
Available datasets are more sparse for incidence, and the patterns
are inconsistent between studies118,126–128. There was an increasing
trend in seroincidence with age during an outbreak for HCoV-229E
in Tecumseh, Michigan118, but a similar analysis of HCoV-OC43
seroincidence in the same outbreak showed no such increase126.
Longitudinal follow-up of ten families in Seattle found a lower rate
of seroconversions among adults compared to children127. A
comparison of a cohort of 21–40-year olds and a cohort of ≥65
years old found no clear difference in incidence between the two age
groups, as measured by seroconversion or PCR-confirmed, HCoV-
associated respiratory illness128. Finally, observational studies have
shown evidence of coronavirus-associated respiratory illnesses in
elderly populations129–131 and across all ages132. Supplementary
Fig. 6 displays age-incidence curves for the four papers with
digitizable data on incidence by age.
Fc-γ-RII-bearing immune cells
(monocyte lineage)
Anti-S1
non-neutralizing
antibody binds
to coronavirus
Increased viral entry
at low concentrations (Wang, 2014)
Replicates
(Jaume, 2011; Yip, 2014)
Replicated, but no viral exit
(Jaume, 2011; Yip, 2014)
Cytokines induced
(Wang, 2014; Fu, 2020)
Cytokines not induced
(Yip, 2016)
Severe disease
(Cameron, 2008; Fu, 2020)
Anti-S2 antibody
and prolonged tissue
destruction
Anti-N
antibody
production Anti-N antibody binds IL-11
an anti-inflammatory
cytokine expressed in
lung, bone marrow
(Cheng, 2005; Yasmon, 2012)
Thrombocytopenia and lymphopenia
Endemic
HCoVs
SARS-CoV
Increase binding of immune cells to lung
epithelial cells treated with IFN-γ via interacting
with annexin A2 at the cell surface
(Lin, 2005; Fang, 2010)
Decreased viral entry at
high concentrations
(Wang, 2014)
A2
Speculations
Observed in vitro
Level of evidence
Observed in humans
Fig. 5 Evidence supporting/contradicting SARS-CoV antibody-related pathogenesis. Supporting evidence given in red and contradicting evidence in
blue. Weaker evidence (speculation in discussions) shown in gray, evidence from in vitro studies in thin lines, and evidence observed in humans in thick
lines. Anti-S1 antibodies triggered upon infection may facilitate entry into immune cells at later stages of the infection if concentration is low. Replication
happens but no virus is released. Consequential induction of cytokines is inconclusive, but if they occur, they are associated with severe disease. Roles of
anti-S2 and anti-N antibodies are supported by binding observations.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-18450-4 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:4704 | https://doi.org/10.1038/s41467-020-18450-4 | www.nature.com/naturecommunications 9
The rapid rise in seroprevalence with age observed in the
literature suggests a force of infection (and thus proportion
seropositive to all serotypes at older ages) high enough to
preclude significant rates of coronavirus infection among older
adults if each serotype confers lifelong, complete homologous
immunity (Fig. 7, red line). On the other hand, short-term,
complete immunity, lifelong partial immunity, and the existence
of multiple genotypes within a single serotype with limited cross-
immunity could explain the age-seroprevalence and age-
incidence curves seen in the literature (Fig. 7).
The review gave rise to several observations that were either
consistent or conflicting across papers. Studies that enrolled
children less than 6 months detected loss of maternal antibodies,
representing a preliminary line of defense for newborn chil-
dren81,82,85,125. Most studies showed no discernible difference in
age-seroprevalence trends or in the overall seroprevalence by strain.
Gao et al.78 found that seroprevalence of HCoV-229E and HCoV-
HKU1 was significantly lower than seroprevalence of HCoV-OC43
and HCoV-NL63. In addition, Chan et al.122 found seroprevalence
to HCoV-HKU1 to be low (21.6% in 31–40-year olds) in Hong
Kong, and stated that this was expected from the low rates of
HCoV-HKU1 among respiratory illnesses. Finally, most studies
measured the presence of binding antibodies in the blood. Of the
studies in Fig. 6, only Cavallaro and Monto118 (red) measured
seropositivity using a neutralization assay. That the seroprevalence
is markedly lower in that study could indicate lower prevalences of
neutralizing antibodies, lower sensitivity of neutralizing versus
binding assays, or lack of correlation between neutralizing and
binding antibodies against endemic coronaviruses.
Regarding the novel coronaviruses, serosurveys of SARS-CoV
confirmed that the rate of asymptomatic or subclinical infection
was very low133. Asymptomatic and subclinical rates of MERS-
CoV are generally higher, but available serosurveys lack the
power to draw strong inference about age trends. A large
serosurvey conducted across Saudi Arabia found that the age of
seropositive individuals was significantly lower than the age of
clinical cases134, while another conducted across multiple
countries in Africa and Asia found no trend in seroprevalence
with age135. Studies of risk factors within camel workers have
either not addressed age as a risk factor136,137 or not found an
association138.
Discussion
We have presented a broad, comprehensive review of multiple
aspects of the literature on antibody immunity to coronaviruses.
We identified a number of key findings. The median time to
detection was the shortest for SARS-CoV-2 (11.0 days; IQR
7.0–14.0 days), followed by SARS-CoV (13.5 days; IQR
10.0–18.0 days) and MERS-CoV (15.0 days; IQR 12.0–18.0 days).
Most long-term studies found that SARS-CoV and MERS-CoV
IgG waned over time (typically detectable up to at least a year),
while others found detectable levels of IgG 3 years post symptom
onset. Antibody kinetics varied across the severity gradient, with
antibodies remaining detectable longer after illness with more
severe symptoms. Human challenge studies with HCoV indicate
that serum and mucosal immune responses (serum IgG, IgA,
neutralizing titer, and mucosal IgA) provide possible correlates of
protection from infection and disease. However, repeat human
challenge experiments with single HCoV suggest that individuals
can be infected with the same HCoV 1 year after the first chal-
lenge, though perhaps experiencing lower severity. There is cross-
reactivity within but minimal reactivity between Alpha- and Beta-
CoVs. While endemic HCoVs rarely induce cross-reactive anti-
bodies against emerging HCoVs, SARS-CoV and MERS-CoV
stimulate antibodies induced by prior HCoV infections. Multiple
mechanisms for immunopathology have been suggested, but no
strong causal evidence exists. The extent to which antibody
responses can in some circumstances contribute to disease
severity is not known. Seroprevalence with the four major
endemic HCoV strains rose rapidly during childhood and
remained high in adults. Median age at first infection with any
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strain was 4.8 years (95% CI 2.5–11.2 years). There was no
clear trend in seroincidence with age, and many studies have
demonstrated incidence of coronavirus infections in elderly
populations. These results suggest a measurable impact of
immunity to coronaviruses on future risk, but this protection may
be transient.
We have suggested a set of search terms to identify relevant
work, and others may expand on this search. Due to the speed of
new research being produced, we limited our systematic review of
SARS-CoV-2 papers to before March 20, 2020. Further evidence
on immune responses to SARS-CoV-2 is likely contained in work
that has since been published. To remain human-focused, we
excluded from the review animal studies and studies of animal
CoVs, but this literature is likely relevant to some areas of the
review. We limited the scope of the review to antibody-mediated
immunity, meaning that understanding of some areas of the
review may be incomplete. Other aspects of immunity, including
the innate and cellular responses, have been shown to be
important in conferring protection at reexposure. Finally, digi-
tized data could be affected by publication bias or other selection
bias, meaning that it might not be representative of data from all
studies. The aim of the pooled analyses was to summarize the
array of studies rather than formally explore hypotheses, and as a
result, the models used are simple. For example, in estimating
force of infection from age-stratified seroprevalence data, we did
not consider other features of a model, such as assay sensitivity,
time- and age-varying force of infections, seroreversion, and
cross-reactivity between strains, that might better explain patterns
seen in the data. Albeit the limitations, there exist multiple
implications for the ongoing SARS-CoV-2 pandemic responses
and future outlooks.
There is a need for development of serological assays with high
sensitivity and specificity to understand the extent of infection in
populations. Evidence from previous emerging CoVs suggests
that false negativity is likely to result from waning of antibody
levels. As most studies on antibody kinetics are on symptomatic
patients, the kinetics in subclinical infections, a significant pro-
portion of SARS-CoV-2 infections139, remains a key gap in the
literature. Serological surveys to describe the extent of infection in
particular populations should account for the dynamics of anti-
body and the potential for infections associated with different
severities of illness to have different antibody responses in their
analysis. Indications that less severe illnesses are associated with
reduced antibody responses suggest that mild cases may pose
challenges to serological assays.
On the other end, the proposed policy of immunity passports
to allow individuals who are presumed to be immune to return to
work once social distancing measures are relaxed requires highly
specific serological tests to mitigate adverse outcomes. Evidence
from past emerging HCoVs suggests low false positivity from
cross-reaction with endemic HCoVs. However, antibody titers do
not necessarily translate to immunity. Challenge studies indicate
multiple candidates that may serve as correlates of protection,
including serum and mucosal measures; however, these will need
specific evaluation for SARS-CoV-2. The knowledge gap in cor-
relates of protection and their durability must be filled before
immunity passports are safe for general use.
Numerous vaccines of varying antigenic compositions are
currently under development140, and polyclonal antibodies from
SARS-CoV-2-recovered patients are being evaluated for treat-
ment141. In this review, we have summarized concerns of theo-
retical dangers from antibodies in the immunopathogenesis of
COVID-19 diseases. These concerns should not hinder the urgent
development of vaccines and therapeutics; however, these hypo-
thetical risks must be squarely addressed. Research in animals,
in vitro, and in humans should be done on immunopathogenesis
of SARS-CoV-2 as an integral component of the development of
antibody therapeutics and vaccines. Compared to other disease
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systems (e.g., dengue), where risk from antibody-mediated
immunopathogenesis is well supported with laboratory, clinical,
and epidemiological data, this potential for immunopathogenesis
in SARS-CoV-2 infections remains speculative142–145. Though
evidence for immunopathogenesis remains limited146, it will be
important to design human trials to provide valid evidence of a
positive effect and detect negative effects should they occur. There
are concerns with antibody treatment, where patients are already
infected and ill-pose lesser concerns. Preventive measures,
including vaccines or passively administered antibodies meant to
lower risk, will require closer attention. Serological responses in
vaccinees should be evaluated to detect potential immuno-
pathogenic effects. Human vaccine trials might start with older
individuals, who per infection are at higher risk of experiencing
severe illness, and as such have a potential benefit-to-risk ratio
from vaccines that is much higher than younger individuals.
Consideration could also be given to post-licensing surveillance
systems designed to detect the remote risks of waning immunity
and subsequent adverse events due to vaccine-mediated
immunopathogenesis.
Key questions for the long-term dynamics of SARS-CoV-2
include whether it is likely to be eradicated, whether widespread
immunity will lead to transient decreases in incidence, and how
long it will take for another large outbreak to occur (Table 1).
Modeling studies will be crucial to answer these questions, but
they will rely on an understanding of immune responses to SARS-
CoV-2 and interactions with other coronaviruses to make rele-
vant predictions. Analysis of datasets, specifically of serosurveys,
needs to account for the kinetics of waning immunity and effects
of imperfect assays to draw meaningful inferences.
Finally, we note that the best evidence for immune responses to
SARS-CoV-2 will come from studies of the virus itself. Such
studies are being performed and reported with unprecedented
speed, but in the absence of firm evidence, many are turning to
the existing coronaviruses as a model. To that end, we have
produced this review to aid researchers in understanding the
scope of the evidence for immune responses to these
coronaviruses.
Methods
Search strategy and selection criteria. We conducted searches of the PubMed
database on March 20, 2020 using the search term “coronavirus” and each of the
following terms or phrases: “serolog*”, “serop*”, “cross reactivity”, “antibod*
human coronavirus”, and “complement fixation”. We also searched for each of
these terms with the search terms “SARS” and “MERS”. Articles were included in
the search, regardless of publication date. Articles included electronic, ahead-of-
print publications available in the PubMed database. We did not attempt to contact
authors to obtain unpublished data. Each abstract was reviewed by two reviewers.
Articles that were not considered applicable were excluded (Supplementary Fig. 1).
We additionally identified relevant articles from the references of other articles
identified by our searches.
Assessment. Abstracts were classified as (1) study of antibody immune responses
to human coronavirus, (2) study of human coronavirus, but not about antibody
immunity, (3) study in nonhumans or basic biological study of virus–antibody
interactions not characterizing actual humans, (4) study in humans not about
coronavirus, (5) in another language, (6) duplicate of another record, or (7)
dead link/bad return/noise. Disagreement between two reviewers on classification
was resolved by a third reviewer. Papers classified in the first category (study of
antibody immune responses to human coronavirus) were reviewed in their entirety
and classified by one reviewer as relevant to one or more of the following:
(1) antibody kinetics, (2) correlates of protection, (3) antigenic diversity and cross-
reactivity, (4) immunopathogenesis, and/or (5) population seroprevalence or
incidence. Papers that were not considered relevant to any of the preceding cate-
gories were excluded.
Data abstraction. Data were digitized from papers according to predefined criteria
for each area of focus, related to accessibility, utility in answering key questions,
and suitability for pooled analyses.
For antibody kinetics and the association of antibody responses with clinical
severity, we shortlisted papers that met the following criteria for data digitization:
(i) antibody responses were provided for at least two distinct points in time and
were relative to a point of infection or symptom onset, or (ii) explicitly discussed
severity of symptoms in relation to antibody response. Data could consist of
multiple measures of antibody kinetics: serological responses for individual patients
(either quantified antibody levels or binary metric of seropositivity), and
(cumulative) proportion of a group of patients that was seropositive or had
seroconverted at different time points. Most studies used more than one assay and
targeted more than one antibody; in these cases, we digitized all the data provided
across assays and antibody types. For the pooled analysis, we excluded studies that
summarized antibody responses across patients, but we nonetheless discussed their
main findings. Where possible, severity associated with different (groups of)
patients was extracted and standardized (Supplementary Table 3). Finally, we also
digitized cut-off points for the assays when given to define limits of detection or
thresholds for positivity, and refer to these as limits of detection. When not
explicitly stated, but a category defined as less than some value exists, we assumed
the value to be the limit of detection (e.g., cutoff of 1:10 is assumed when “<1:10”
was present).
Studies on correlates of protection targeted for inclusion required a defined
exposure, pre-existing antibody level (either antibody concentrations and/or
serostatus) and outcomes as either virologically confirmed or serologically
confirmed infection.
For cross-protection and antigenic diversity, instances of human infections
with a particular HCoV and titers against itself and the others were
summarized. Acute, convalescent, and fold rise in titers were digitized as brackets
of possible values along with the number of individuals associated with those data
points (e.g., a titer reported as 1:160 with the next serial dilution tested at 1:320
could take a value from 1:160 to 1:320). For MERS-CoV and SARS-CoV, acute
titers were assumed to be the lowest reported in that study (either <1:10 or <1:20)
as prior exposure was unlikely (Leung et al.133; Degnah et al.135). If not reported,
fold rises were calculated using lower ends of both time points. If measurements
included the lowest reported, we assumed a titer of five to avoid having a zero as
the denominator. All data points are accompanied by the type of test/assay
performed.
For population seroprevalence, we determined papers that reported the number
of positive tests out of the number sampled in at least two age groups in a
population (by seroconversion with/without symptoms or PCR-confirmed
symptomatic infections) if sampling was performed independently of symptoms.
Data extracted from the text, tables, or figures include strain/virus tested for;
whether seropositivity, seroconversion, or incidence was measured; time period of
the study for seroincidence studies; assay type; target antigen; cut point for defining
seropositivity/seroconversion; bounds of age category; number of samples; number
of positive samples. In plotting the data, if the upper bound of the highest age
category could not be identified, we assumed that it was 20 years above the lower
bound based on inspection of the highest age categories in other studies.
For diagnostic serological assays and immunopathogenesis, we compiled and
summarized findings from the categories without data extraction. Data extracted
for correlates of protection and antigenic diversity were summarized and visualized
without the attempt to draw a pooled conclusion.
Pooled analyses. We conducted pooled analyses in two areas.
To analyze the antibody kinetics and association of antibody responses with
clinical severity, we summarized the approximate time to detection for three sets of
studies. The first set includes studies with a cumulative number of positive cases
over time. Each additional positive case added to the cumulative curve was
assumed to be a new detected case at that time point. This is approximate only
because cumulative curves sometimes decline (Supplementary Fig. 2), indicating
that some participants were lost to follow-up. Second, we identified the data that
described either seropositivity as a function of time, or measures of antibodies with
a reported cutoff. Data were included if (i) the first seropositive time point was
within 3 weeks of illness onset, or (ii) the first estimate(s) were negative, but a
subsequent measurement within 3 weeks of the first was positive. Third, if a study
only reported times to seroconversion, those values were used.
We estimated the annual force of infection from age-stratified seroprevalence
data, assuming that individuals acquire infection with a single, strain-specific force
of infection that is constant in time using standard method 18, and that once an
individual becomes seropositive, they remain seropositive for the remainder of
their lifetime. We estimated the total force of infection (FOI) from the four major
endemic strains by drawing 100,000 bootstrap samples of four strain-specific FOIs
and calculating the sum across strains. Age at first infection is given by the inverse
of the total FOI. Finally, we visually compared age-incidence trends to curves
generated by catalytic models with four proposed mechanisms for CoV immunity
(see “Supplementary Appendix” for details).
Hypothetical age-seroincidence curves using different models for endemic
HCoV immunity were built using extensions of the simple catalytic model in which
each individual is exposed to a constant force of infection λ, and the probability of
being seropositive at age a is given by S(a)= 1–e–λa, and the incidence rate from
age a to a+ 1 is given by I(a)= e–λa–e–λ(a+ 1). For example, if the first infection
grants partial homologous immunity, reducing the hazard of infection by a
factor ρ < 1, the incidence rate from age a to a+ 1 is given by I(a)= e–λa(1–e–λ)+
(1–e–λa)(1–e–ρ λa).
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